Therapeutic and functional subject matter expertise is a core attribute of Prescient’s value proposition. We have openings in our London, New York and San Francisco offices for seasoned subject matter experts (SMEs) with demonstratable expertise in oncology, hematology or immunology.
SMEs will play a critical role in both leading and advising on client engagements, ensuring the analysis, implications and recommendations delivered to clients are accurate and impactful. They will also act as mentors to the broader team, ensuring we nurture talent and expedite development. The role offers the ideal opportunity for executives with deep subject knowledge to continue to develop their expertise, to keep abreast of new market developments and to build on their commercial experience.
Prescient is a high-performing, values-driven environment where we pride ourselves on our commitment to client excellence and people development.
SMEs will demonstrate robust knowledge in one of the three priority therapy areas, as well as clinical development, regulatory affairs and/or market access. They will have hands-on experience in developing or launching pharmaceutical products, either from the client side or in an advisory capacity. They will have a strong knowledge of the EU or US regulatory and reimbursement environments, so they are well positioned to advise clients on the critical success factors associated with expediting development timelines and achieving optimal labels and broad patient access.
SMEs will also be strong mentors who derive satisfaction from developing bright young executives, typically with either MD or PhD backgrounds.
The successful candidates will spend 80% of their time in their local office and the remainder undertaking domestic and international travel to clients, conferences and other Prescient offices.
At least 15 years of relevant therapeutic (oncology, hematology or immunology) and functional (clinical development, regulatory affairs or market access) experience gained from working within biopharmaceutical consultancies or the biotechnology/pharmaceutical industry is essential. The preferred candidate will have a PhD in oncology or immunology or an MD with a specialty in oncology or immunological disease.